Q-omics provides the consensus-scored NIPSNAP3B profile across patient tissues and cancer cell-line models. NIPSNAP3B expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, NIPSNAP3B is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, NIPSNAP3B RNA expression shows 19,650 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight UVM, KIRC, and THYM as cancer lineages where NIPSNAP3B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NIPSNAP3B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NIPSNAP3B survival associations across molecular data types. NIPSNAP3B RNA expression shows survival associations in the most cancer types (19), followed by mutation status (4) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NIPSNAP3B RNA expression–survival associations across cancer types. High NIPSNAP3B expression shows unfavorable associations in LGG, but favorable associations in UVM, PAAD, KIRC, UCS and LUAD. The UVM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for NIPSNAP3B RNA expression.
This table summarizes NIPSNAP3B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 2. The strongest signals are observed in KIRC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for NIPSNAP3B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NIPSNAP3B shows lower tumor expression in KIRC, KICH, HNSC, BRCA, BLCA and UCEC. The KIRC box plot shows higher NIPSNAP3B RNA expression in normal versus tumor tissue (log2 FC = −0.537, t-test p = .001).
This table shows molecular features associated with NIPSNAP3B in patient tissues and cancer cell lines. In patient samples, NIPSNAP3B shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, NIPSNAP3B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUSC, while CRISPR and shRNA rows add functional-dependency signals in OVARY and BLOOD_Lymphoma.
